Status:
COMPLETED
Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.
Eligibility Criteria
Inclusion
- Patient greater than or equal to 18 years of age,
- non-smokers,
- diagnosed with asthma, with an FEV1 less than or equal to 70 percent of predicted normal,
- stable use of Beta agonist
- daily use of inhaled steroids for one year
Exclusion
- Patients with other significant diseases other than asthma, requiring oxygen,
- intubated within 5 years,
- asthma exacerbation within 6 weeks of trial,
- use of unstable doses (greater than 10 mg/day of prednisone or equivalent) of steroids,
- participating in another interventional trial
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT00096616
Start Date
November 1 2004
Last Update
November 1 2013
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
620 South 20th Street, NHB 104
Birmingham, Alabama, United States
2
Cooper Green Hospital
Birmingham, Alabama, United States
3
Southern California Clinical Trials
Lakewood, California, United States
4
Boehringer Ingelheim Investigational Site
Palmdale, California, United States